We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+3.37%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$37.4B
AUM Growth
-$234M
(-0.62%)
Cap. Flow
-$832M
Cap. Flow
% of AUM
-2.23%
Top 10 Holdings %
Top 10 Hldgs %
26.05%
Holding
2,051
New
47
Increased
483
Reduced
1,317
Closed
203
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$240M |
| 2 |
Sysco
SYY
|
+$180M |
| 3 |
Synopsys
SNPS
|
+$83.9M |
| 4 |
C.H. Robinson
CHRW
|
+$42.1M |
| 5 |
United Bankshares
UBSI
|
+$38.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
3M
MMM
|
+$216M |
| 2 |
Apple
AAPL
|
+$189M |
| 3 |
Microsoft
MSFT
|
+$115M |
| 4 |
Meta Platforms (Facebook)
META
|
+$68.7M |
| 5 |
Broadcom
AVGO
|
+$65.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.13% |
| 2 | Consumer Staples | 11.3% |
| 3 | Industrials | 10.65% |
| 4 | Financials | 9.24% |
| 5 | Consumer Discretionary | 9.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
Zentalis Pharmaceuticals
ZNTL
$308M
| $49.8K | ﹤0.01% |
12,184
-3,252
| -21% | -$36.3K |
|
|
SFIX
1752
Stitch Fix
SFIX
$478M
| $49.7K | ﹤0.01% |
11,985
-4,092
| -25% | -$11.1K |
|
1753
Heron Therapeutics
HRTX
$86.3M
| $48.5K | ﹤0.01% |
13,869
-4,735
| -25% | -$14.5K |
|
1754
Chegg
CHGG
$108M
| $48.2K | ﹤0.01% |
15,258
-5,210
| -25% | -$25.9K |
|
|
HOUS
1755
DELISTED
Anywhere Real Estate
HOUS
| $47.8K | ﹤0.01% |
14,450
-7,349
| -34% | -$34.3K |
|
1756
Sutro Biopharma
STRO
$379M
| $47.8K | ﹤0.01% |
1,632
+538
| +49% | +$21.3K |
|
1757
Xperi
XPER
$365M
| $47.8K | ﹤0.01% |
+5,819
| New | +$55K |
|
1758
Willdan Group
WLDN
$1.1B
| $47.7K | ﹤0.01% |
+1,652
| New | +$49.3K |
|
|
CVAC
1759
DELISTED
CureVac
CVAC
| $47.1K | ﹤0.01% |
13,847
-1,844
| -12% | -$6.03K |
|
|
RVNC
1760
DELISTED
Revance Therapeutics, Inc.
RVNC
| $46.7K | ﹤0.01% |
18,157
-3,747
| -17% | -$12.8K |
|
1761
Planet Labs
PL
$7.3B
| $43.7K | ﹤0.01% |
23,479
-8,014
| -25% | -$15.4K |
|
|
AUTL
1762
Autolus Therapeutics
AUTL
$386M
| $42.8K | ﹤0.01% |
+12,313
| New | +$53.1K |
|
1763
Lantronix
LTRX
$236M
| $41.8K | ﹤0.01% |
+11,785
| New | +$42.2K |
|
1764
Cerus
CERS
$587M
| $41.8K | ﹤0.01% |
23,768
-8,114
| -25% | -$14.5K |
|
1765
Zumiez
ZUMZ
$320M
| $41.6K | ﹤0.01% |
+2,134
| New | +$37K |
|
1766
Ribbon Communications
RBBN
$354M
| $39.1K | ﹤0.01% |
11,898
-4,063
| -25% | -$12.4K |
|
1767
Evolv Technologies
EVLV
$943M
| $39K | ﹤0.01% |
15,286
-5,218
| -25% | -$17.3K |
|
1768
FuelCell Energy
FCEL
$1.7B
| $38.9K | ﹤0.01% |
2,031
-4,805
| -70% | -$129K |
|
1769
Westrock Coffee
WEST
$741M
| $38.9K | ﹤0.01% |
+3,804
| New | +$39.1K |
|
1770
Bit Digital
BTBT
$484M
| $38.6K | ﹤0.01% |
12,132
-4,141
| -25% | -$10.1K |
|
|
TRUE
1771
DELISTED
TrueCar
TRUE
| $37.5K | ﹤0.01% |
11,996
-4,094
| -25% | -$12K |
|
1772
Advantage Solutions
ADV
$484M
| $37.5K | ﹤0.01% |
466
-158
| -25% | -$14.7K |
|
1773
Fate Therapeutics
FATE
$281M
| $37.2K | ﹤0.01% |
11,351
-3,876
| -25% | -$17K |
|
|
BLUE
1774
DELISTED
bluebird bio
BLUE
| $36.8K | ﹤0.01% |
1,870
-517
| -22% | -$10.4K |
|
1775
8x8 Inc
EGHT
$247M
| $36.7K | ﹤0.01% |
16,532
-5,643
| -25% | -$13.7K |
|
Similar funds
ProShare Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, ProShare Advisors held 2,051 positions worth $37.4B, down 0.62% from $37.6B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
ProShare Advisors's Q2 2024 filing shows 47 new, 483 increased, 1,317 reduced and 203 closed positions. Its largest new stake was KKR & Co: 135,149 shares worth $14.2M. The largest sale was 3M, an estimated $216M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 29% a quarter earlier, followed by Consumer Staples and Industrials.
- ProShare Advisors's largest Q2 2024 buy was KKR & Co: 135,149 shares worth $14.2M.
- ProShare Advisors added most to Qualcomm in Q2 2024, an estimated $240M increase.
- ProShare Advisors's biggest Q2 2024 reduction was 3M, cutting an estimated $216M.
- ProShare Advisors fully exited Leggett & Platt in Q2 2024, selling an estimated $24.6M.
- ProShare Advisors's ten largest holdings make up 26% of its $37.4B portfolio in Q2 2024.
- ProShare Advisors opened 47 new positions and closed 203 in Q2 2024.
- ProShare Advisors's portfolio value fell 0.62% quarter-over-quarter to $37.4B.
Based on ProShare Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.